Tokio Marine Asset Management Co. Ltd. cut its position in Edwards Lifesciences Corporation (NYSE:EW) by 24.1% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 2,596 shares of the medical research company’s stock after selling 826 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Edwards Lifesciences Corporation were worth $307,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Sabal Trust CO raised its stake in Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock valued at $347,000 after buying an additional 14 shares during the period. Alexandria Capital LLC raised its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the period. Quadrant Capital Group LLC raised its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares during the period. Rehmann Capital Advisory Group raised its stake in Edwards Lifesciences Corporation by 1.6% in the first quarter. Rehmann Capital Advisory Group now owns 3,393 shares of the medical research company’s stock valued at $319,000 after buying an additional 55 shares during the period. Finally, M Holdings Securities Inc. raised its stake in Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock valued at $389,000 after buying an additional 62 shares during the period. 84.15% of the stock is owned by institutional investors.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 116.19 on Monday. The stock has a 50 day moving average price of $117.23 and a 200 day moving average price of $104.41. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The firm has a market capitalization of $24.53 billion, a PE ratio of 35.24 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. During the same period in the prior year, the company earned $0.76 EPS. The firm’s revenue was up 10.9% on a year-over-year basis. Equities analysts forecast that Edwards Lifesciences Corporation will post $3.64 earnings per share for the current fiscal year.

WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/07/tokio-marine-asset-management-co-ltd-has-307000-stake-in-edwards-lifesciences-corporation-nyseew.html.

A number of research firms have recently issued reports on EW. Canaccord Genuity restated a “buy” rating and issued a $155.00 price target (up from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Royal Bank Of Canada restated a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Cowen and Company restated an “outperform” rating and issued a $135.00 price target (up from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Barclays PLC upped their price target on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, July 27th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $130.00 price target (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $121.13.

In other Edwards Lifesciences Corporation news, VP Patrick B. Verguet sold 22,631 shares of the business’s stock in a transaction on Friday, May 19th. The shares were sold at an average price of $113.16, for a total value of $2,560,923.96. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Catherine M. Szyman sold 4,681 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 125,512 shares of company stock valued at $14,460,159. 2.13% of the stock is owned by corporate insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.